Eohilia

Launched

Budesonide oral suspension · Eosinophilic esophagitis

Topical corticosteroid (oral suspension)

Feb 2024 (US)

Launch readiness

+1 pts MoM

Regulatory

Trial momentum

Evidence

Access / HTA

Digital momentum

Competitive

Milestone rail

Feb 2024

FDA approval

May 2024

US commercial launch

2025

Payer coverage expansion

2027

Pediatric expansion readout (planned)

Clinical trials

ClinicalTrials.gov · Sep 2026

Active P3

Enrollment

55%

Completion in

20mo

Competing programs

Enrollment vs target55%

Publications

PubMed · Sep 2026

Last 12m

Growth

26%

+26%

Top-journal share

18%

Gastroenterology · 4Clin Gastro Hepatol · 6ACG/UEGW · 14Other · 15

Regulatory

openFDA · Sep 2026

FDA approval Feb 2024Orphan Drug

3 of 4 tracked milestones complete

HTA / access

Price databases · Sep 2026

NICE

n/a

G-BA

n/a

HAS

n/a

CADTH

planned

PBAC

n/a

List price (yr)

$2k

Class median

$36k

below class

Competitor landscape

Public pipelines · Sep 2026

Rival	Status	Launch in	Readiness	Δ efficacy
Dupixent Sanofi / Regeneron	Marketed SoC	launched	100	0 pts
Swallowed topical steroids Off-label	Generic	launched	90	-22 pts
APT-1011 Ellodi	Phase 3 (revived)	30 mo	40	-8 pts

x: efficacy Δ vs SoC · y: access readiness

Risk / opportunity radar

Composite model · Sep 2026

CEO take

Only FDA-approved oral suspension for EoE — strong differentiation
Dupixent dominates biologic segment; Eohilia wins on oral, on-demand use
Digital momentum 79/100: patient community unusually vocal in EoE
Access 72/100 — step-edit policies remain the top barrier
Opportunity: pediatric label expansion work

Digital signal layer

Multi-source listening · Sep 2026

Search interest index

Google Trends

68idx+4 pts

Congress abstracts 12m

ASCO / ASH / EHA / AAN / ACG

21abstracts+2 new

KOL share of voice

X / LinkedIn / podcasts

26%+1.8 pts

News & PR velocity

Press wires & trade media

15/mo+3 items

Patient community volume

Reddit / Inspire / patient forums

18.6k posts+0.6 k

Community sentiment

NLP over community posts

81/100+1 pt

Payer / formulary chatter

Payer bulletins / guidelines

38idx+5 pts